Document Detail

Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
MedLine Citation:
PMID:  19614796     Owner:  NLM     Status:  MEDLINE    
Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States. There is a 3-fold increase in the prevalence of coronary heart disease, myocardial infarction, and stroke due to the coagulation, hemodynamic, and metabolic abnormalities seen in these individuals. The use of aspirin for secondary prevention and, to a lesser degree, primary prevention of cardiovascular events is a well-established standard of care. However, in patients with diabetes or the cardiometabolic syndrome, the role of aspirin in prevention of cardiovascular events remains controversial. In this review, the authors examine the clinical trial data on the use of aspirin in diabetes and the cardiometabolic syndrome for cardiovascular protection. They also explore, in addition to aspirin's effects on platelet aggregation, some of the mechanisms by which aspirin may favorably alter the course of atherosclerosis, effects on endothelial function, and glycemia.
Michael Gardner; John Palmer; Camila Manrique; Guido Lastra; David W Gardner; James R Sowers
Related Documents :
22801566 - Gonadotroph pituitary macroadenoma inducing ovarian hyperstimulation syndrome: successf...
15802076 - Biliopancreatic diversion as a novel approach to the hair-an syndrome.
19840386 - Metabolic syndrome in children and adolescents - criteria for diagnosis.
3965406 - Metabolic and mitochondrial morphological changes that mimic reye syndrome after endoto...
11761556 - Sudden development of bilateral cataract in a child with dubowitz syndrome: a case report.
23927776 - Linkages between goal attainment and quality of life for individuals with chronic fatig...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review    
Journal Detail:
Title:  Journal of the cardiometabolic syndrome     Volume:  4     ISSN:  1559-4572     ISO Abbreviation:  -     Publication Date:  2009  
Date Detail:
Created Date:  2009-07-20     Completed Date:  2009-09-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101284690     Medline TA:  J Cardiometab Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  96-101     Citation Subset:  IM    
Diabetes and Cardiovascular Center, University of Missouri School of Medicine and Truman VA Hospital, Columbia, MO 65212, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / therapeutic use*
Blood Coagulation / drug effects
Blood Glucose / metabolism
Blood Platelets / drug effects
Cardiovascular Agents / therapeutic use*
Cardiovascular Diseases / blood,  etiology,  prevention & control*
Diabetes Complications / blood,  etiology,  prevention & control*
Diabetes Mellitus, Type 2 / blood,  complications,  drug therapy*
Endothelium, Vascular / drug effects
Metabolic Syndrome X / blood,  complications,  drug therapy*
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Blood Glucose; 0/Cardiovascular Agents; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecu...
Next Document:  Resveratrol: biologic and therapeutic implications.